Disclosures VS: Research funding/grant support for clinical trials: Roche/Genentech, Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfasigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines, Loxo Oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda, and National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals; Travel: Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte; Consultancy/Advisory board: Helsinn, LOXO Oncology/Eli Lilly, R-Pharma US, INCYTE, QED Pharma, Medimmune, Novartis. Other: Medscape. DBS has consulted for/received honoraria from Loxo Oncology, Lilly Oncology, Pfizer, Vivideon Therapeutics, QED Therapeutics and Illumina. TAC is a co-founder of Gritstone Oncology and holds stock; receives research funding from Bristol-Myers Squibb (BMS), Pfizer, Illumina, Eisai, AstraZeneca, NysnoBio. He is a paid consultant of BMS, Illumina, AstraZeneca, An2H and holds patents for the use of TMB for prediction of clinical benefit from immune checkpoint inhibitors and receives royalties. RK receives research funding from Genentech, Merck Serono, Pfizer, Boehringer Ingelheim, TopAlliance, Takeda, Incyte, Debiopharm, Medimmune, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Omniseq and Guardant, as well as consultant and/or speaker fees and/or advisory board for X-Biotech, Loxo, Neomed, Pfizer, Actuate Therapeutics and Roche, has an equity interest in IDbyDNA and CureMatch Inc, is a cofounder of CureMatch and serves on the Board of CureMatch and CureMetrix.